Bruker Corporation (BRKR) | The Buildout — AI Infrastructure
The Verdict
Bruker builds high-performance scientific instruments and analytical systems — the machines researchers and quality-control engineers use to examine materials at microscopic, molecular and cellular levels. Its link to the AI buildout is narrow but real: semiconductor metrology tools sold to chip makers for the memory and advanced-packaging work AI demand drives, and SciY, a lab-software business that makes laboratory data "AI-ready." Everything else — magnetic resonance, mass spectrometry, X-ray, microscopy and diagnostics — serves life-science research, hospitals, industry, security and energy-research customers.
| Market Cap | — |
| Revenue (TTM) | $3.5B |
| Revenue Growth | +1.6% |
| EBITDA Margin (TTM) | 10.2% |
| Net Debt | $1.7B |
| Earnings Beats | 4 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Order momentum: BSI organic bookings grew 10% YoY in Q2 2026, with book-to-bill above 1.0 for a fourth consecutive quarter.
- Cost savings: 2026 annualized target on track, described as "north of $140M," plus an additional $20M expected in FY2027 from the new operating structure.
- Semiconductor metrology: more than $300M annual revenue at about 30% EBIT margin, with H1 2026 organic orders up more than 30% and organic revenue up more than 15%.
- BEST superconductor outlook: about $600M of multiyear orders over December–April from all three major MRI OEM customers; Q2 2026 organic revenue up 8.9%.
- Balance sheet: net leverage improved to 2.8x at June 30, 2026 from 2.9x, and Q2 2026 operating cash flow improved $50M YoY.
What We’re Watching
- Q4 2026 execution: revenue around $1B with management estimating only about 50-67% in backlog; the quarter depends on a $20M semiconductor shift and an ultra-high-field NMR installation.
- U.S. academic/government: Q2 2026 revenue down more than $15M YoY, and management is not counting on a recovery in guidance.
- One-time tariff refunds: added about 200 bps to Q2 2026 operating margin and about $0.06 to EPS; Q3 margin and EPS are guided slightly lower sequentially.
- A $135M noncash goodwill impairment in automation and spatial biology drove a GAAP diluted loss per share of $0.41 in Q2 2026.
The thesis is intact but back-half loaded. Bruker delivered the return to organic growth it promised, held FY2026 organic, margin and EPS guidance, and raised the cost-savings story twice. The revenue guide and the year's shape now rest on a single large quarter that management estimates is only about 50-67% covered by backlog. The open question: does the deep-tech order book convert on schedule in Q4 2026 and into 2027, or slip again?
Earnings Beat
In Q2 2026, Bruker reported revenue of $839M, up 5.2% YoY, with organic growth of 2.8% — or 3.4% excluding tariff refunds. Non-GAAP gross margin was 52.1%, up 350 bps YoY, and non-GAAP operating margin was 14.1%, up 510 bps, including about 200 bps from U.S. tariff refunds. Non-GAAP EPS was $0.49, up 53%. The standout operating metric was the order book: BSI organic bookings rose 10% and book-to-bill was above 1.0 for a fourth consecutive quarter.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $838M | $823M | $797M | +5.2% |
| Gross margin | 49.6% | 47.3% | 44.9% | +470bps |
| EBITDA | −$7M | $103M | $68M | −110.7% |
| EPS | $-0.34 | $0.09 | $0.05 | −782.0% |
| BSI book-to-bill | >1.0 | >1.0 | n/a | — |
| Non-GAAP EPS | $0.49 | $0.31 | $0.32 | +53.1% |
the orders are remarkable for the first half and even more so in Q2… we think this is very sustainable this year and next… the visibility of the sector for the next 6 quarters plus seems excellent.— Frank Laukien, CEO, 2026-08-04
Management tone: On the Q1 2026 call, management was cautiously optimistic — framing Q1 as a beat against a soft expectation and pointing to a Q2 return to organic growth. The Q2 2026 call was more mixed and more direct: management delivered the promised return but at the low end, and immediately reset Q3 lower. Confidence was channeled into orders and semiconductor visibility, while U.S. academic/government was named as the clear outlier. Management also acknowledged it did not have exact figures for Q4 backlog coverage when pressed.
Management Guidance
For FY2026, management guides reported revenue of $3.54B–$3.57B (+3%–4%), organic growth of 1%–2%, an M&A contribution of 1.5%, and an FX tailwind of 0.5%. Non-GAAP operating margin expansion is guided at +250–300 bps and non-GAAP EPS at $2.10–$2.15 (+15%–17%). The reported revenue range was lowered from $3.57B–$3.60B solely on a change in the FX assumption; organic, margin and EPS guidance were held. For Q3 2026, management expects about $20M of semiconductor revenue to shift into Q4, organic revenue roughly flat to up slightly, and a slight sequential decrease in operating margin and EPS. Q4 2026 is guided to meaningful sequential and YoY increases in organic revenue, operating margin and EPS, with revenue around $1B. For FY2027, management says it intends to grow margins well above 100 bps and deliver double-digit, hopefully mid-teens, non-GAAP EPS growth — not yet formal guidance.
Trajectory
Revenue has stabilized: Q2 2026 revenue was $839M, up 5.2% YoY, with organic growth of 2.8% — a return to organic growth after declines. H1 2026 revenue was $1.66B, up 3.9%, though H1 organic revenue was down 0.8%. Margins expanded sharply in Q2: non-GAAP gross margin was 52.1%, up 350 bps, and non-GAAP operating margin was 14.1%, up 510 bps, helped by cost actions and a one-time U.S. tariff refund worth about 200 bps. Orders are running ahead of revenue — BSI bookings rose 10% organically with book-to-bill above 1.0 for a fourth quarter — but the growth is uneven: biopharma, semiconductor metrology, energy research and security detection are strong, while U.S. academic/government, food safety, automation, and parts of industrial and spatial biology remain weak.
The Model
The model projects FY+1 revenue of $3,560M and EBITDA of $595M, a 16.7% margin. For FY+2, it projects revenue of $3,800M and EBITDA of $680M, a 17.9% margin. The near-term anchor is the deep-tech order book — semiconductor metrology, energy research and security detection — plus the cost-savings program. The FY+2 step-up assumes that order strength gradually converts into revenue and that margin expansion continues.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $3.4B | $3.6B | $3.8B |
| YoY Growth | — | +3.6% | +6.7% |
| EBITDA | $411M | $595M | $680M |
| EBITDA Margin | 12.0% | 16.7% | 17.9% |
Projections are the median of 5 independent model runs. The model’s revenue sits 1.0% above analyst consensus.
For FY2026, management guides reported revenue of $3.54B–$3.57B (+3%–4%), organic growth of 1%–2%, an M&A contribution of 1.5%, and an FX tailwind of 0.5%. Non-GAAP operating margin expansion is guided at +250–300 bps and non-GAAP EPS at $2.10–$2.15 (+15%–17%). The reported revenue range was lowered from $3.57B–$3.60B solely on a change in the FX assumption; organic, margin and EPS guidance were held. For Q3 2026, management expects about $20M of semiconductor revenue to shift into Q4, organic revenue roughly flat to up slightly, and a slight sequential decrease in operating margin and EPS. Q4 2026 is guided to meaningful sequential and YoY increases in organic revenue, operating margin and EPS, with revenue around $1B. For FY2027, management says it intends to grow margins well above 100 bps and deliver double-digit, hopefully mid-teens, non-GAAP EPS growth — not yet formal guidance.
What Could Go Right — and Wrong
- Semiconductor metrology orders convert on schedule, with Q4 2026 revenue landing near $1B and semi revenue growth converging toward order growth.
- U.S. academic/government orders inflect positive, adding revenue that is not in current guidance.
- Cost savings phase in fully — about $30M delivered in Q2 2026 — supporting the FY2027 margin ambition.
- Microbiology and MALDI re-accelerate to mid-to-high-single-digit growth on large Q3/Q4 deals, including Latin America.
- FY2027 margin and earnings ambitions are formalized into guidance with a credible bridge.
- Q4 2026 slips again — another semiconductor delay or a missed ultra-high-field NMR installation — leaving the year's growth dependent on Q4 timing.
- U.S. academic/government weakness persists, capping the core instrument franchise.
- AI-driven memory and advanced-packaging capex moderates beyond 2027, undercutting the strongest order line.
- Spatial biology or automation losses continue, implying prior M&A remains value-destructive.
- Input costs (electronics components, helium) or FX turn more adverse than the guide assumes.
Looking Ahead
Over the next 12 months the story turns on two questions: whether the deep-tech order book converts into revenue, and whether the FY2027 margin and EPS ambition becomes formal guidance. Q3 2026 earnings tests semiconductor delivery timing and the Q4 setup. Q4 2026 is expected to carry the year, with meaningful margin and EPS increases on better mix and significantly higher volume. Management points to the cost-savings ladder and a multiyear deep-tech order book as the basis for 2027.
- Q3 2026Q3 2026 earnings — Tests semiconductor delivery timing and the large-Q4 setup.
- Q4 2026Q4 2026 revenue ramp — Load-bearing quarter; only ~50-67% in backlog.
- Q4 2026Ultra-high-field NMR delivery — Management cites a greater-than-80% installation success ratio.
- FY2027FY2027 guidance — Tests the margin >100 bps and mid-teens EPS ambition.
- 2026Wave platform FDA clearance — Promised for 2026; no update on Q1 or Q2 calls.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $3.4B | $3.4B | $3.5B | +2.1% |
| Gross Margin | 48.9% | 46.0% | 46.7% | 297bps |
| EBITDA | $437M | $411M | $357M | -6.0% |
| EBITDA Margin | 13.0% | 12.0% | 10.2% | 102bps |
| Net Income | $113M | −$9M | −$71M | -107.6% |
| Free Cash Flow | $136M | $43M | $94M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)46.7%
- EBITDA Margin (TTM)10.2%
- Net Margin (TTM)-2.0%
- ROIC2.4%
- FCF Conversion26.3%
- SBC / Revenue0.0%
The Company
Bruker is, in its own 10-K words, "a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels." Its platforms include magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology and molecular spectroscopy. It sells the tools scientists and quality-control engineers use, plus the aftermarket service and consumables that follow an installed base.
Bruker reports four segments — BSI BioSpin, BSI CALID, BSI NANO and BEST — and on 2026-07-01 adopted a new operating structure with four groups: Bruker Biosystems, Bruker Nano, BMID and BEST. The company runs a global owned and leased manufacturing and R&D footprint concentrated in Germany (Ettlingen, Berlin, Bremen, Nehren, Karlsruhe, Bergisch Gladbach, Hanau), with sites in Switzerland, Austria, Israel, Malaysia, Scotland and the United States, including a Del Ray Beach, Florida site tied to semiconductor mask repair. Management said the new operating structure is expected to drive additional cost reductions in fiscal 2027.
Business Segments
Supply Chain
Bruker buys specialized components and raw materials and sells instruments into biopharma, academia, industry, semiconductor fabs and security and energy-research customers. No neighbor transcript names Bruker directly; read-through comes from shared end-markets.
More on BRKR: Earnings recap